40
Kite (Gilead) presented updated, pooled analysis at ASH 2025 for Yescarta$^circledR$ (axicabtagene ciloleucel) in relapsed/refractory large B-cell lymphoma (R/R LBCL), integrating ZUMA-7 (4-year) and ALYCANTE (2-year) data, including ASCT-ineligible patients.
Key 2-Year Pooled Outcomes:
-
Overall Survival (OS): 64.9% (vs. $approx 20%$ historical rates).
-
Event-Free Survival (EFS): 45.2%.
-
Durable Response: 12-month DOR of 61%.
-
Safety/QoL: Consistent, manageable safety profile across 232 patients. Sustained quality-of-life improvement seen after 100–150 days.
Conclusion: Data reinforces Yescarta’s position as second-line standard of care with potential curative intent across diverse R/R LBCL populations.